Apoptosis and liver fibrosis: antifibrotic strategies

Biomed Pharmacother. 1998;52(6):259-63. doi: 10.1016/S0753-3322(98)80011-5.

Abstract

Hepatic fibrosis is a frequent response of the liver and is similar to parenchymal wound healing in other tissues. Apoptosis has been described in different models of liver fibrosis. Hepatic stellate cells are the main source of extracellular matrix. At present, one can speculate that inhibition of apoptosis is responsible for activation and proliferation of hepatic stellate cells. Thus, the inhibition of hepatic stellate cell apoptosis could be a target for antifibrotic strategies. Until now, no drugs have been clearly shown to be effective in reducing specifically the development of hepatic fibrosis. However, serious candidates are presently under studies in clinical trials, including especially alpha interferon and phosphatidylcholine.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis*
  • Humans
  • Interferons / therapeutic use
  • Liver / drug effects
  • Liver / pathology*
  • Liver / physiopathology
  • Liver Cirrhosis / pathology*
  • Liver Cirrhosis / physiopathology
  • Liver Cirrhosis / therapy*
  • Liver Cirrhosis, Biliary / pathology
  • Liver Cirrhosis, Biliary / physiopathology
  • Liver Cirrhosis, Biliary / therapy

Substances

  • Interferons